Update on novel therapies for pancreatic neuroendocrine tumors
JOP. 2012 Jul 10;13(4):372-5.
Oberstein PE, Saif MW.
Terapia di combinazione con octreotide, bevacizumab e pertuzumab in tumori neuroendocrini pancreatici (pNET).
Octreotide-bevacizumab-pertuzumab/tumori neuroendocrini pancreatici.